- Strides Pharma Science Ltd has partnered with Kenox Pharmaceuticals Inc. to develop and file multiple nasal spray products for the US market.
- The collaboration combines Strides’ commercial capabilities with Kenox’s expertise in Orally Inhaled and Nasal Drug Products (OINDPs).
Strides Pharma Science Ltd announced that its wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has signed a strategic partnership with US-based Kenox Pharmaceuticals Inc. The agreement covers the joint development and regulatory filing of several nasal spray products intended for the US market.
Kenox is a contract development and manufacturing company specialising in Orally Inhaled and Nasal Drug Products (OINDPs). While specific product details remain confidential, the partnership is designed to target a range of therapeutic indications.
Aditya Kumar, Executive Director, Business Development at Strides, said: “Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain.”
The collaboration aligns Kenox’s formulation and development expertise with Strides’ manufacturing and commercial strengths. According to both companies, the partnership is intended to accelerate the availability of affordable nasal spray therapies for patients in the US.
With the US facility investment cited by Strides, the deal is positioned as part of the company’s wider strategy to expand into nasal spray technology and strengthen its pipeline in the OINDP segment.
